Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global Transcriptional Changes Following Statin Treatment in Breast Cancer.
Bjarnadottir O, Kimbung S, Johansson I, Veerla S, Jönsson M, Bendahl PO, Grabau D, Hedenfalk I, Borgquist S. Bjarnadottir O, et al. Among authors: veerla s. Clin Cancer Res. 2015 Aug 1;21(15):3402-11. doi: 10.1158/1078-0432.CCR-14-1403. Epub 2015 Apr 3. Clin Cancer Res. 2015. PMID: 25840970 Clinical Trial.
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, Söderberg M, Walz TM, Fernö M, Hatschek T, Hedenfalk I; TEX study group. Kimbung S, et al. Among authors: veerla s. Clin Cancer Res. 2016 Jan 1;22(1):146-57. doi: 10.1158/1078-0432.CCR-15-0487. Epub 2015 Aug 14. Clin Cancer Res. 2016. PMID: 26276891
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, Saracco A, Hellström M, Veerla S, Paquet E, Bendahl PO, Fernö M, Bergh J, Loman N, Hatschek T, Hedenfalk I; PROMIX Trialists Group. Kimbung S, et al. Among authors: veerla s. Int J Cancer. 2018 Feb 1;142(3):618-628. doi: 10.1002/ijc.31070. Epub 2017 Oct 13. Int J Cancer. 2018. PMID: 28940389 Free PMC article. Clinical Trial.
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Kaminska K, Akrap N, Staaf J, Alves CL, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg Å, Pérez-Fidalgo A, Ditzel HJ, Bosch A, Honeth G. Kaminska K, et al. Among authors: veerla s. Breast Cancer Res. 2021 Feb 18;23(1):26. doi: 10.1186/s13058-021-01402-1. Breast Cancer Res. 2021. PMID: 33602273 Free PMC article.
How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer.
Saghir H, Veerla S, Malmberg M, Rydén L, Ehinger A, Saal LH, Vallon-Christersson J, Borg Å, Hegardt C, Larsson C, Haidar A, Hedenfalk I, Loman N, Kimbung S. Saghir H, et al. Among authors: veerla s. Cancers (Basel). 2022 Aug 18;14(16):4000. doi: 10.3390/cancers14164000. Cancers (Basel). 2022. PMID: 36010992 Free PMC article.
44 results